THe NeWSLeTTer oF THe DaMoN ruNYoN CaNCer reSearCH FouNDaTIoN www.daMOnrunyOn.

Org

1.877.7CanCer
Fa l l / WINTeR 2012

reCeNT DISCoVerIeS aND ProgreSS

CLINICaL SuCCeSS For NeW, MuLTI-CaNCer IMMuNoTHeraPY
Former Damon runyon Clinical Investigator Charles g. Drake, MD, PhD, announced the success of two Phase I clinical trials to test immunotherapy treatments that block the PD-1 protein and the PD-L1 protein. PD-1 and PD-L1 are turned on at high levels in certain types of melanoma, lung, kidney and other cancers and protect tumors from the immune system. once either protein was turned off, the immune system went to work, significantly reducing tumors in 20-25% of patients.

inside

Runyon 5K at Yankee Stadium Breaks $2M Mark

02

Esmeralda Chauca, cancer survivor and Runyon 5K participant

Partnering to Cure Pediatric Cancers

It began when I was four years old. I was trying to go to bed when I started to feel pain in my legs, says esmeralda Chauca, a 13 year-old cancer survivor from New York. after they took my blood, the doctor told my mom and I that I had aLL, short for acute Lymphoblastic Leukemia. I didnt know what it meant until they told me I had cancer of my blood.
esmeralda wrote to us after signing up for the Damon runyon 5K at Yankee Stadium. after years of treatment, I am now in remission and have been for almost 5 years! I really have my oncologist and my chemotherapy nurse to thank. I just wish that a cure could be found right now so that all the people and kids like me could no longer suffer or die from cancer. We could not agree more. Nothing is as important as saving the lives of the 11,000 children across the country who are diagnosed with cancer each year. That is why we partnered with the Sohn Conference Foundation this year to create the new Damon runyon-Sohn Pediatric Cancer research Fellowship. In July, we selected the first class of awardees, including angela J. sievert, mD, of The Childrens Hospital of Philadelphia. I was so frustrated by the lack of innovative treatments for children that I decided to make it both my clinical and research focus, angela says. She is working to develop more effective treatments for children with brain tumors, the leading cause of cancer-related death in children. She aims to target mutations in the BraF gene that can drive cancer growth and are prevalent in pediatric astrocytomas. leo Wang, mD, PhD, of the Dana-Farber Cancer Institute in Boston, studies leukemia, which is caused by rapidly and inappropriately dividing blood cells that derive from leukemia stem cells (LSCs) and are highly resistant to chemotherapy. Leos goal is to understand what makes LSCs different from normal blood stem cells and to develop novel therapies for childhood blood cancers. lara e. Davis, mD, of oregon Health and Science university in Portland, studies osteosarcoma, a bone cancer responsible for over 8% of all pediatric cancer deaths. She is identifying genetic pathways in individual tumor samples that can be targeted by cancer therapies and aims to design therapeutic combinations to prevent drug resistance.

WorLDS FIrST aNaLYSIS oF T-CeLL LYMPHoMa geNoMe

Damon runyon Clinical Investigator andrew L. Feldman, MD, completed the first genome-wide analysis of peripheral T-cell lymphomas, a set of aggressive cancers of the immune system. He found 13 genetic abnormalities, five of which relate to the p53 protein, known for its role in preventing tumors. researchers plan to use this new information to improve diagnostic tests for T-cell lymphomas, most of which are difficult to classify and treat. See a video of Dr. Feldman discussing his work at: bit.ly/drfeldman

From Clinic to Laboratory and Back Again

03

04
New Class of Fellows is Our Largest in a Decade

WroNg geNe NuMBer BeHIND SoMe TeSTICuLar CaNCerS?

a recent discovery by Damon runyon Clinical Investigator Zsofia K. Stadler, MD, is shedding light on an overlooked cause of some testicular cancers. Tumors often result from genetic mutations, but Zsofia has found that some testicular tumors are caused by copy number variations having fewer or more copies of a gene than necessary. In a recent study of patients, 7% of those with testicular germ cell tumors had copy number variations that were spontaneous and not inherited from their parents.

Alumni Profile: Lus Parada, PhD

05

Broadways Best Seats for the Holidays

06

iNtroDuCiNG ChaNGe4CaNCer.orG
Change4Cancer.org is our newlylaunched Facebook initiative. one coin for each of your friends on Facebook is all that it takes for you to make a difference against cancer. give it a try, and please send any feedback to change4cancer@gmail.com.

Damon Runyon-Sohn Fellows: Angela J. Sievert, MD; Leo Wang, MD, PhD; and Lara E. Davis, MD

Page

our WorK our eVeNTS

HONORING A VISIONARY BUSINESS LEADER & PHILANTHROPIST

our annual Breakfast in New York City honored Miles S. Nadal, Chairman and Ceo of MDC Partners, one of the worlds largest marketing firms, and raised $1.3M to support Damon runyon scientists.
Mr. Nadal was introduced by Damon runyon Board Member Leon g. Cooperman. Miles is an extraordinary example of someone who has dared to dream and dared to make a difference, Cooperman said. Like Damon runyon, he believes, quite simply, that great talent can achieve great things. The mornings program featured talks by two Damon runyon Innovators and David M. Livingston, MD, Deputy Director of the Dana-Farber/Harvard Cancer Center. explaining the importance of Damon runyon, Livingston called it a little gem in the middle of New York that scours the great universities of the world for young geniuses, then supports them at a time in their careers when they most need it.
TOP: Miles Nadal Fellow Shijing Luo, PhD, with honoree Miles Nadal INSET, LEFT: Damon Runyon Board Member Dr. Livingston INSET, RIGHT: Attendees enjoy coffee and conversation before the event

Im so happy to step foot on the same ground as some of my favorite players. Nothing beats a victory lap around the field at the Cathedral of Baseball to celebrate being cancer free for one year! Justin Ferrarella, cancer survivor & Runyon 5K participant

RUNYON 5K AT YANKEE STADIUM BREAKS $2M MARK

Four thousand runners, baseball fans, cancer survivors and supporters of cancer research took part in our annual Damon runyon 5K at Yankee Stadium on august 12, raising $742,000 for cancer research. Since 2009, the runyon 5K has raised more than $2M to fund Damon runyon scientists. Mark goodmaster, of North Branford, Connecticut, took home the Top Fundraiser prize after bringing in $17,450. He received tickets to the Yankees Inside experience. Before watching a game from Field MVP section seats, he and a guest met with Yankees third baseman eric Chavez, took a photo with the 2009 World Series trophy and received a guided tour of the stadium. Former New York Yankees Mickey rivers and ron Blomberg kicked off the 5K with master of ceremonies Michael gargiulo, co-anchor of NBC4s Today in New York.
RIGHT: Top fundraiser Mark Goodmaster with Damon Runyon President & CEO Lorraine Egan

View great photos, videos and more at:

www.damonrunyon.org/yankeestadium or www.facebook.com/runyon5k
Page 2

our WorK our SCIeNTISTS

FROM CLINIC TO LABORATORY AND BACK AGAIN

Carey K. anders, Md

Translating laboratory discoveries into life-saving clinical tools is a critical step in defeating cancer. unfortunately, we face a national shortage of clinical investigators capable of making that translation possible. Since 2000, Damon runyon has worked with partners in industrymost recently through our accelerating Cancer Cures initiative to invest $41 million in the careers of 64 of these physician-scientists, including six new Damon runyon Clinical Investigators selected in June.

In approximately 30% of women with advanced Her2-positive breast cancer, the cancer spreads to the brain. While this cancer type can be controlled in most parts of the body, few treatments can cross the blood-brain barrier. Carey has identified a genetic pathway that can be targeted by the existing therapy everolimus (afinitor), which crosses the blood-brain barrier. She is now leading a Phase II clinical trial to determine whether everolimus combined with chemotherapy could be effective in treating breast cancer brain metastases. Mentors: Lisa A. Carey, MD, and Charles M. Perou, PhD, University of North Carolina, Chapel Hill, North Carolina

that focuses exclusively on DIPg. He is studying proteins that drive the tumors growth in hopes of developing a new treatment. Mentors: Darell D. Bigner, MD, PhD, and Katherine E. Warren, MD, Duke University, Durham, North Carolina

sarat Chandarlapaty, Md, phd

The PI3K signaling pathway is mutated in more than 70% of breast cancer cases, making it a promising target for treatment. However, drugs designed to target PI3K have shown limited success. Sarat is studying how tumor cells adapt to resist these treatments and has already discovered that cancer cells use a cellular mechanism called negative feedback to reactivate PI3K or activate pathways not blocked by anti-PI3K drugs. Mentors: Neal Rosen, MD, PhD, and Clifford A. Hudis, MD, Memorial Sloan-Kettering Cancer Center, New York, New York

Oren J. BeCher, Md
Diffuse intrinsic pontine glioma, or DIPg, is an incurable and fatal brain cancer that mostly strikes young children. oren leads one of only a few laboratories in the world

New Class of Fellows is Our Largest in a Decade

In July, we awarded $3.3 million to 21 of the nations top minds in cancer research. The Fellowship gives each recipient $156,000 to pursue their own out-of-the-box ideas at a critical point in their careers. They join an elite group of 3,350 scientists funded by Damon runyon since the Fellowship began in 1946.
Gira BhaBha, PhD, with her sponsor ronald D. Vale, PhD, at the university of California, San Francisco, California, is using electron and light microscopy techniques to study the structure and atomic motions of dynein, a molecular motor protein that walks along tracks in the cell called microtubules. Dyneins role in cell transport and division makes it a potential target for cancer treatment. alistair N. BoettiGer, PhD, with

system called microglia communicate to other cell types during nerve injury. He seeks to identify cell-to-cell signals that contribute to chronic pain induced by tumors.
aNNe h. Bothmer, PhD (Jake Wetchler Foundation Fellow for Pediatric Innovation) with her sponsor Pier Paolo Pandolfi, MD, PhD, at Beth Israel Deaconess Medical Center, Boston, Massachusetts, is studying the function of ribosomes, cellular machines responsible for making protein. She plans to characterize how ribosomes in cancerous cells differ from those in normal cells, and to test whether these differences contribute to diseases such as acute myeloid leukemia (aML). aNGela N. BrooKs, PhD, with her sponsor Matthew L. Meyerson, MD, PhD, at Dana-Farber Cancer Institute, Boston, Massachusetts, is analyzing cancer genome sequence data to identify DNa mutations that affect rNa splicing. Her work will provide further understanding of the role of splicing alterations in cancer. Gamze . CamDere, PhD, with her sponsor Douglas e. Koshland,

PhD, at the university of California, Berkeley, California, is using structural biological analysis and in vitro assays to understand how a protein called cohesin interacts with DNa. a better understanding of cohesin will provide important insights into chromosome biology, as well as the pathology of cancer.
steveN D. CaPPell, PhD, with

DamiaN C. eKiert, PhD, with his

his sponsor Xiaowei Zhuang, PhD, at Harvard university, Cambridge, Massachusetts, aims to understand the molecular mechanisms of gene silencing through the application of novel super-resolution microscopy techniques. gene silencing is an important process whereby genes that are not needed in certain tissues are turned off. Loss of silencing can lead to the expression of genes that promote cell proliferation and migration, leading to cancer.
ChristoPher J. BohleN, PhD,

his sponsor Tobias Meyer, PhD, at Stanford university, Stanford, California, is applying quantitative time-lapse microscopy, live-cell fluorescent reporters and mathematical modeling to understand the molecular events that allow cells to enter the cell cycle. The beginning of the cell cycle is deregulated in nearly all types of cancers.
elie J. DiNer, PhD, with his sponsor

sponsor Jeffery S. Cox, PhD, at the university of California, San Francisco, California, is exploring the complex interactions between the host immune system and Mycobacterium tuberculosis, the pathogen that causes tuberculosis in humans. In order to survive and replicate inside host cells, M. tuberculosis must evade detection by the immune system and interfere with multiple antimicrobial pathways that would otherwise destroy the bacteria. His work may shed light on how cancerous cells evade detection by similar mechanisms.
miNGye FeNG, PhD, with his sponsor Irving L. Weissman, MD, at Stanford university, Stanford, California, is studying immunosurveillance in metastasis, which is mediated by cells called macrophages. Cancer cells are confronted with multiple challenges during metastasis, including macrophage-mediated cell removal in the circulation and distant organs. He will focus on defining how metastatic cancer cells evade removal and developing strategies to promote the clearance of these cells by macrophages.

with his sponsor Ben a. Barres, MD, PhD, at Stanford university School of Medicine, Stanford, California, is studying how cells of the nervous

russell e. Vance, PhD, at the university of California, Berkeley, California, seeks to understand how the innate immune system distinguishes between self- and non-self nucleic acids. Cancerous cells undergo uninhibited cell growth that typically remains undetected by the immune system.

Page

2012 Clinical Investigator Continuation grants

ryan B. COrCOran, Md, phd
Mutations in the BraF gene occur in 1015% of colorectal cancers. unfortunately, drugs that target mutant BraF have not been effective for colorectal cancer patients. Through lab studies and clinical trials, ryan plans to identify other key survival signals in BraF mutant colorectal cancers that can be targeted, in combination with BraF inhibitors, to improve treatment. Mentors: Jeffrey A. Engelman, MD, PhD, and Keith T. Flaherty, MD, Massachusetts General Hospital, Boston, Massachusetts favor of killing tumor cells and increasing patient survival. Mentors: Mario R. Capecchi, PhD, and Sunil Sharma, MD, University of Utah, Salt Lake City, Utah

hOlBrOOK e. KOhrt, Md, phd

Monoclonal antibodies that target cancer are among the most notable scientific advances of the last 30 years, saving thousands of lives. The response rate among those with advanced cancer, however, is less than 25%. Holbrook has identified an antibody that enhances immune cells function, resulting in greater damage to targeted cancer cells. He is developing new therapies that improve the activity of monoclonal antibodies. ultimately, he hopes to eliminate the need for chemotherapy. Mentor: Ronald Levy, MD, Stanford University, Stanford, California
IMAGES L to R: Carey K. Anders, MD; Oren J. Becher, MD; Sarat Chandarlapaty, MD, PhD; Ryan B. Corcoran, MD, PhD; Kevin B. Jones, MD; Holbrook E. Kohrt, MD, PhD

In June, we also awarded Continuation grants to two Damon runyon Clinical Investigators whose work has shown exceptional promise. each will receive an additional $300,000 to use over two years.

aNDreW L. FeLDMaN, MD
Improving Diagnosis and Treatment of T-Cell Lymphomas
Mayo Clinic, rochester, Minnesota See page 1 for Andrew's most recent discovery

Kevin B. JOnes, Md
Synovial sarcoma is a rare cancer that primarily affects adolescents and young adults. It has an unusual balance of celldeath and cell-survival signals that make it very resistant to chemotherapies that would normally kill a tumor. Kevins work will improve understanding of this unique balance and how we might topple it in

WILLIaM Y. KIM, MD
Damon Runyon-Merck Investigator

Targeting New Pathways to Treat renal Cell Carcinoma

university of North Carolina, Chapel Hill, North Carolina

li he, PhD, with his sponsor Norbert

Karl a. merriCK, PhD, with his

Perrimon, PhD, at Harvard Medical School, Boston, Massachusetts, is studying how organ size and quality are controlled. Cells compete with each other during tissue growth or regeneration for survival. The winners proliferate in response to the activation of apoptosis (programmed cell death) in the losers. This process can eliminate tumor cells at an early stage but may be hijacked by cancer cells to invade the healthy tissue.
melaNie issiGoNis, PhD (HHMI Fellow) with her sponsor Phillip a. Newmark, PhD, at the university of Illinois at urbana-Champaign, Illinois, studies the mechanisms by which somatic stem cells produce germ cells, which give rise to either egg or sperm. germ cells and cancer cells share several characteristics such as immortalization (transformation) and migration (metastasis). a wide range of cancers arise when germ cell developmental pathways are erroneously activated in somatic cells. shiJiNG luo, PhD (Miles S. Nadal Fellow) with her sponsor elaine V. Fuchs, PhD, at The rockefeller university, New York, New York, aims to identify genes that control stem cell activation and migration into a wound site upon injury. Chronic injury and irregular wound healing are correlated with greater susceptibility to skin cancer and metastasis.

sponsor Michael B. Yaffe, MD, PhD, at Massachusetts Institute of Technology, Cambridge, Massachusetts, is studying how inflammation affects the development of colorectal cancer and its response to chemotherapy. By using animal models and highly quantitative systems-based approaches, he hopes to identify novel therapies and develop methods to predict the efficacy of drug treatment.
miChael e. PaColD, mD, PhD

into the dynamics required for autophagy and how they may be disrupted in cancer.
lisa r. raCKi, PhD (HHMI Fellow) with her sponsor Dianne K. Newman, PhD, at the California Institute of Technology, Pasadena, California, is studying metabolism of compounds called polyphosphates in Pseudomonas aeruginosa, a bacterial pathogen that can lead to lethal infections in immunocompromised cancer patients. a better understanding of polyphosphate metabolism may aid in the design of treatments for cancer-associated pathogens. ChristoPher J. shoemaKer, PhD, with his sponsors Vlad Denic,

understand how several species of bacteria naturally produce MNPs with exquisite control over size and shape that is unmatched by current chemical synthesis methods.
stePhaNie C. WeBer, PhD (HHMI Fellow) with her sponsors Clifford P. Brangwynne, PhD, and Howard a. Stone, PhD, at Princeton university, Princeton, New Jersey, is investigating control of cell size. She aims to understand how the nucleolus, an organelle that has been implicated in tumor formation, contributes to cell, tissue and body size. Cancer cells often differ in size from normal cells, suggesting that the mechanisms controlling cell size break down during the course of the disease. aruN P. Wiita, mD, PhD, with his sponsor James a. Wells, PhD, at the university of California, San Francisco, California, is using a powerful technique called mass spectrometry to isolate and identify proteins degraded during cell death and released into the bloodstream shortly after starting chemotherapy. His goal is to identify proteins that can serve as rapid and inexpensive markers of chemotherapeutic efficacy, enabling more effective and individualized regimens for cancer patients.

(Sally Gordon Fellow) with his sponsors David M. Sabatini, MD, PhD, and Nathanael S. gray, PhD, at the Whitehead Institute for Biomedical research, Cambridge, Massachusetts, studies dehydrogenases, a class of metabolic enzymes that synthesize the building blocks required for the survival and proliferation of cancer cells. His goal is to develop compounds that block the activity of dehydrogenases essential for the growth of treatment-resistant cancers, with a focus on certain breast cancers.
laura PoNtaNo vaites, PhD, with her sponsor J. Wade Harper, PhD, at Harvard Medical School, Boston, Massachusetts, focuses on autophagy, a critical process that allows cells to recycle their components to survive nutrientdepleted conditions. The proposed work will provide detailed insight

PhD, and andrew W. Murray, PhD, at Harvard university, Cambridge, Massachusetts, is studying autophagy, a process of cellular housekeeping and energy generation. The activation of autophagy can facilitate cancer drug resistance. He ultimately seeks to limit the effects of drug resistance during cancer treatment.
miChael J. smaNsKi, PhD (HHMI Fellow) with his sponsor Christopher a. Voigt, PhD, at Massachusetts Institute of Technology, Cambridge, Massachusetts, is examining magnetic nanoparticles (MNPs), which possess unique physical properties that have led to several clinical applications in cancer diagnosis and therapy. He aims to

Page

our PeoPle aBouT uS

DO TumOrs Have sTem CeLLs? a PrOFiLe OF aLumNus Lus ParaDa

a recent Time magazine article asked one of the most perplexing questions about cancer: How can it return after it has apparently been eradicated?
Former Damon runyon Fellow Lus F. Parada, PhD whose work was featured in the articlehas developed a hypothesis that may finally explain why, at least in brain cancers, tumors return and how that recurrence might be prevented. Cancer has long been thought to be caused by rapidly proliferating cells that spread out of control. Thus, most therapies target cells that are rapidly dividing. Lus and an expanding group of fellow scientists now believe that not all cancer cells are created equal. He posits that tumors are composed of a hierarchy of cells, with cancer stem cells at the top. These cancer stem cells generate cells that rapidly divide, but do not do so themselves. If true, it would mean that many standard treatments are leaving the real culprits behind. using a mouse model of glioblastoma, Lus and his team designed a way to label what they hypothesized were cancer stem cells and their rapidly-proliferating offspring. Next, they administered temozolomide, the gold standard treatment for glioblastoma, to kill dividing cells. When they withdrew the temozolomide, the tumors began to re-grow. They were able to conclude that temozolomide was destroying the rapidlyproliferating cells but leaving the cancer stem cells intact to re-grow the tumor. as a next step, Lus is hoping to develop compounds that are toxic to cancer stem cells. Not only will this be more effective against glioblastoma, but it will save healthy dividing cells and eliminate the side effects of many cancer therapies. Lus applied for a Damon runyon Fellowship in 1985 so that he could study the relationship between cancer-causing genes and embryonic development. Despite the fact that my proposal was somewhat far-fetched, Damon runyon supported me. That opportunity really transformed the way that I do science, he remembers. Because his award was so essential to his early career, Lus later served on the Fellowship award Committee, selecting the next generation of Damon runyon scientists. It was an act of love, he notes. Damon runyon is identifying the very best to make sure they are at the best places and doing the best work. Ive seen many of the Fellows that I evaluated become colleagues, so its a process that has worked tremendously well over time.

Lus Parada, PhD

WaYS To gIVe
DoNate oNliNe You can easily donate online via our secure website at www.damonrunyon.org

ABOUT US
To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides todays best young scientists with funding to pursue innovative cancer research. Damon Runyon scientists, including 11 Nobel Laureates, have made some of the most important discoveries in cancer research, including:

To learn more about ways to support the Damon runyon Cancer research Foundation, contact us at 212.455.0500 or visit www.damonrunyon.org/donate
aNNual aND moNthly GiviNG annual or monthly gifts are easily made and very much appreciated. You can donate by mail, by phone or via our secure website at www.damonrunyon.org triButes Make a donation in memory or in honor of a loved one, or for birthdays and celebrations. a card will be sent on your behalf.

PlaN to FuND Future BreaKthrouGhs When you remember the Foundation in your will or estate, you are funding future cancer breakthroughs. Many planned giving strategies exist that may provide you with significant tax savings. For advice, please contact us. sPoNsor a sCieNtist Sponsor a Damon runyon scientist and play an active role in the development of future cancer treatments and cures. We will name the award for you, your family, or in honor of someone you choose. BroaDWay tiCKets enjoy access to top house seats at Broadway shows and support cancer research. gift certificates are available, and we welcome corporate clients. Call 212.455.0550 or visit www.damonrunyon.org/broadway

1954

Confirming the link between cigarette smoking and lung cancer

1970
Identifying the first cancercausing gene

2011

Leading studies resulting in approval of breakthrough treatments for advanced melanoma

IN 66 YEARS, THE FOUNDATION HAS INVESTED MORE THAN $250 millioN AND FUNDED MORE THAN 3,350 sCieNtists.

100%
OF DONATIONS FUND CANCER RESEARCH
our low administrative costs are paid from Damon runyon Broadway Tickets and our endowment.

Walter Winchell

Damon Runyon

our HISTorY
The Foundation was created in 1946 following the death from cancer of Damon Runyon, the writer whose beloved Broadway stories inspired the musical Guys and Dolls. Walter Winchell, a famous journalist and commentator, founded the fund and led it with the help of celebrities including Marlene Dietrich, Bob Hope, Marilyn Monroe and Joe DiMaggio.

Page

one exchange Plaza, 55 Broadway, Suite 302, New York, New York 10006

NoNProFIT org. uS PoSTage PaID PerMIT #247 WILKeS-Barre, Pa

Partnering to Cure Pediatric Cancers runyon 5K at Yankee Stadium Breaks $2M Mark From Clinic to Laboratory and Back again alumni Profile: Lus Parada, PhD Broadways Best Seats for the Holidays

Broadways Best Seats for the Holidays

This upcoming holiday season, call Damon runyon Broadway tickets to get your family and friends great seats to a hit Broadway show while supporting cancer research. We rely on word of mouth, so please tell your friends about our service or introduce them with our Broadway gift certificates. They can choose the shows and performances themselves! our decades-long relationship with Broadway theaters plays a major role in supporting our brilliant young scientists. Tickets are competitively priced, and half of the cost is a tax-deductible contribution to cancer research. to reserve tickets or buy a gift certificate, call 212.455.0550 on weekdays between 9 a.m. and 5 p.m. et or visit www.damonrunyon.org/broadway.
BoarD oF DireCtors
Chairman alan M. Leventhal vice Chairmen Leon g. Cooperman David M. Livingston, MD Sanford W. Morhouse, esq. David M. Beirne Michael L. gordon Steven J. Burakoff, MD William L. Carroll, MD gary e. erlbaum Thomas J. Fahey, Jr., MD Buck French Dale F. Frey elaine V. Fuchs, PhD richard B. gaynor, MD Todd r. golub, MD Scott greenstein Steve Hayden William W. Helman Jay W. Ireland Steven a. Kandarian Noah Knauf ronald Levy, MD David g. Marshall John H. Myers richard J. oreilly, MD andrew S. rachleff Scott ryles Karen D. Seitz William r. Sellers, MD Samuel C. Silverstein, MD

2012 FaLL seasON sHOws

septeMBer Chaplin a new musical about the legendary Charlie Chaplin. nOveMBer a Christmas story, the musical a new musical based on the holiday movie.

Las Vegas. Starring Henry Winkler and Cheyenne Jackson. rebecca a new musical, based on the classic Daphne du Maurier novel, portrays the life of an insecure young woman who marries a wealthy widower with a terrible secret. scandalous: the life and trials of aimee semple mcPherson a new musical based on the life of media superstar evangelist aimee Semple McPherson. a womans passion for saving souls matched her passion for making sensational headlines.

annie The spirited redheaded orphan and her scruffy mutt Sandy make their way back to Broadway this coming Fall. Dead accounts Theresa rebeck's new comedy starring Katie Holmes and Norbert Leo Butz.

deCeMBer the anarchist David Mamet's new play. Starring Patti LuPone and Debra Winger.

Glengarry Glen ross David Mamet's Pulitzer Prize-winning drama. Starring al Pacino and Bobby Cannavale. the heiress The play is a representation of a lonely heiress, her domineering father and the handsome suitor she falls in love with over her father's objections. Starring Jessica Chastain, Dan Stevens and David Strathairn. the Performers a new comedy about two old friends reconnecting at the adult Film awards in

OCtOBer Grace a dark comedy about a devout young couple starting a new life in Florida with big plans of opening a chain of gospelthemed motels. Starring Paul rudd and edward asner.

Golden Boy a revival of Clifford odet's drama, based on one mans struggle to choose between a promising career as a classical musician or a fighter in a boxing ring.

Who's afraid of virginia Woolf? a revival of edward albees drama. Starring Tracy Letts and amy Morton.

elf Based on the 2003 holiday movie, elf is about a boy raised by Santa's elves who comes to New York City to find out about his true identity.

One Exchange Plaza 55 Broadway, Suite 302 New York, NY 10006 Administration 212.455.0500 Fax 212.455.0509 Broadway Ticket Sales 212.455.0550 To receive our newsletter via email, please contact us at 1.877.7CANCER or info@damonrunyon.org www.damonrunyon.org

Premier CirCle
WheN you JoiN the Damon runyon Premier Circle, you receive special early access to our limited-supply, premium house seats. You also receive two complimentary tickets to a show of your choice, special invites to our theater benefits for reduced prices and recognition in our annual report. Most importantly, you are investing in breakthroughs. to learn more, call 212.455.0550 or email tickets@damonrunyon.org.

Page